Type 2 diabetes trials recruiting in Alabama

All Type 2 diabetes trials nationally

Cities in Alabama

Recruiting trials in Alabama

• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Anniston, Birmingham
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
  NCT07351058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Guntersville
• A Low-Carb Approach to Treat Type 2 Diabetes in Pediatric Patients
  NCT06902077 · Phase: Not applicable (e.g. observational or device study) · Ages: 12 Years to 18 Years · Sex: All (male and female) · Alabama: Birmingham
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham, Dothan
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
  NCT07662044 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham, Daphne
• A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
  NCT07662109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Huntsville, Mobile, Sheffield
• A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
  NCT07668388 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Alabama: Birmingham
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
  NCT07564414 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham, Pelham
• A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
  NCT07654374 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Alabama: Birmingham
• A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
  NCT07340320 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Alabama: Birmingham, Huntsville
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
  NCT07282600 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham, Cullman
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Tuscaloosa
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham, Huntsville
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Dothan, Huntsville
• A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
  NCT07662213 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
  NCT07754461 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
  NCT07533175 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
  NCT07797335 · Phase: Phase 3 · Ages: 45 Years and older · Sex: All (male and female) · Alabama: Birmingham, Fairhope, Montgomery
• Advancing Diabetes Management for People With Physical Disabilities Optimally Through Primary Care-Based Telehealth (ADDOPT)
  NCT07032844 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 89 Years · Sex: All (male and female) · Alabama: Birmingham
• CGM for Management of Type 2 Diabetes in Pregnancy
  NCT06628453 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 50 Years · Sex: Female · Alabama: Birmingham
• DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
  NCT06525259 · Phase: Not specified · Ages: 8 Years to 15 Years · Sex: All (male and female) · Alabama: Birmingham
• Denosumab for Type 1 Diabetes
  NCT06524960 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 50 Years · Sex: All (male and female) · Alabama: Birmingham
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Anniston, Fairhope, Guntersville
• FELLAShip to Better Health
  NCT07220213 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Alabama: Birmingham
• Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
  NCT06906640 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
  NCT06906627 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
  NCT05390892 · Phase: Phase 4 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Alabama: Huntsville
• Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
  NCT06964087 · Phase: Phase 2 · Ages: 18 Years to 50 Years · Sex: All (male and female) · Alabama: Birmingham
• Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
  NCT07502508 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Alabama: Birmingham
• Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
  NCT07502495 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Alabama: Birmingham
• Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
  NCT07271186 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Alabama: Huntsville